EMA squeezes PIPs, wants firms to run more trials in children
This article was originally published in Scrip
The European Medicines Agency has confirmed to Scrip’s sister journal, Scrip Regulatory Affairs, that its pediatrics committee (PDCO) is planning to revoke class waivers for pediatric investigation plans because the waivers are preventing the agency from requesting studies in children, especially in oncology. The plan was briefly mentioned in the minutes of the 5-7 September 2012 PDCO meeting, which were published online on 11 October 2012.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-one guidance documents have been posted on the tracker since its last update.
Almost three dozen countries have shown support for the alternative mechanism put forward by the World Health Organization to ensure that IP issues do not stand in the way of providing access to COVID-19 medicines, vaccines and diagnostics to ‘all of humanity.’
Regulatory and scientific discussions undertaken by the European Medicines Agency’s human medicines evaluation committee are finding their way into a new internal repository.